BioCryst Pharma (BCRX) Update on Strategy, Pipeline and Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Wall Street indexes fall, with Iran and earnings season in focus
- NVIDIA reports 9.3% passive stake in Nebius
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
BioCryst Provides Update on Strategy, Pipeline and Outlook
July 11, 2018 8:00 AM EDTRESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) (BioCryst or the Company), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today provided an update on the Companys strategic and financial outlook as a standalone company following the recent termination of its merger agreement with Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) (Idera).
Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, said, We are moving forward executing our standalone strategy with a great deal of confidence in our... More
